Passage Bio Inc. (PASG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
PASG Chart
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Passage Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $24.09 | $13.83 | -$10.26 | -42.59% |
 Yiheng Capital Management Yiheng Capital Management LP | 86,097 | $811,350.33 | $403,794.93 | -$407,555.4 | -50.23% |
| IM Ilko Menkov Vestal Point Capita LLP | 305,000 | $2.45M | $1.52M | -$927,200 | -37.86% |
| HAS Hayley A. Snell LRI Investments, LLC | 12 | $96 | $58.68 | -$37.32 | -38.87% |
 Winfried Buchbauer Erste Asset Management GmbH | 85,262 | $693,994.07 | $424,604.76 | -$269,389.31 | -38.82% |
Passage Bio Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Geulah Livshits Chardan Capital | -18,179.47 | $123,145.33 | $89,261.22 | $33,884.11 | 27.52% |
Passage Bio Inc. (PASG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Passage Bio Inc. ever had a stock split?
Passage Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | William Chou CEO | NASDAQ (CM) Exchange | 702712209 CUSIP |
| US Country | 24 Employees | - Last Dividend | 14 Jul 2025 Last Split | 28 Feb 2020 IPO Date |
Overview
Passage Bio, Inc. is a pioneering genetic medicines company dedicated to developing transformative gene therapies for central nervous system (CNS) diseases. Founded in 2017 and based in Philadelphia, Pennsylvania, the company has established strategic collaborations to propel its groundbreaking research, including partnerships with the University of Pennsylvania's Gene Therapy Program and Catalent Maryland, Inc. By concentrating on genetic solutions for severe neurological conditions, Passage Bio aims to unlock new possibilities for patients facing limited treatment options.
Products and Services
Passage Bio, Inc. has embarked on the development of several promising gene therapies targeting specific CNS diseases, each at different stages of development:
- PBGM01: Developed as a therapy for infantile GM1 gangliosidosis, PBGM01 delivers a functional GLB1 gene to encode ß-galactosidase enzyme, aiming to address the underlying cause of this rare, inherited neurological disorder.
- PBFT02: Targeting Frontotemporal Dementia (FTD) caused by progranulin (PGRN) deficiency, PBFT02 introduces a functional granulin (GRN) gene to encode progranulin, potentially slowing or halting disease progression in affected individuals.
- PBKR03: This therapy is devised for infantile Krabbe disease, offering a functional GALC gene encoding galactosylceramidase, a crucial enzyme that is typically deficient in patients with this condition, thereby addressing the root cause of the disease.
- PBML04: Focused on treating metachromatic leukodystrophy, PBML04 is another gene therapy under development that aims to rectify the genetic defects leading to this rare and often fatal neurological condition.
- PBAL05: Designed for patients with amyotrophic lateral sclerosis (ALS), PBAL05 is exploring gene therapy methods to treat this progressive neurodegenerative disease, potentially offering hope to those with genetic forms of ALS.
- Other Program: Passage Bio is also working on a gene therapy for Huntington's disease, aiming to develop a treatment for this inherited condition that causes the progressive breakdown of nerve cells in the brain.
